Vectura CFO Sanguine Despite Flutiform Phase III COPD Trial Miss
Executive Summary
Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.
You may also be interested in...
Q&A: Vectura's Leaders Explain Synergies And Priorities For Merged Company
Vectura's CEO James Ward-Lilley and incoming CFO from Skyepharma, Andrew Derodra, sat down with Scrip and explained where they see the excitement, synchronization and R&D fusion for the larger company.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.